Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin cardiovascular outcomes study in type 2 diabetes with established vascular disease
NL-OMON47681Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ertugliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Pfizer. Primary endpoint: Primary cardiovascular endpoint. Started Sep 2014; status: active, not recruiting.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON47681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47681.